Almirall has fresh funds and wants to spend them on acquiring new dermatology assets, CEO Eduardo Sanchiz said following the surprise announcement that the Spanish firm is to sell its respiratory portfolio to AstraZeneca.
The deal with AZ gives Almirall $875m up front and up to $1.22bn in development, launch and sales milestones, plus royalties (scripintelligence.com, 30 July 2014)